Key result
Elevated baseline levels of soluble ST2 and Galectin-3 were not independently associated with all-cause mortality in patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy.
Why the study?
Although sST2 may be a biomarker of chronic systolic heart failure, its role and the role of Galectin-3 in hypertrophic cardiomyopathy remain unclear.
Do Soluble ST2 and Galectin-3 levels predict all-cause mortality in patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy?
Cohort (n=125)
No
Do Soluble ST2 and Galectin-3 levels predict all-cause mortality in patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy?
Hazard Ratio: 1.15 (95% CI 0.98–1.27)
p-value: p=0.143
While sST2 and Gal-3 are elevated in HCM patients, they do not independently predict all-cause mortality after ventricular septal myectomy, whereas maximum wall thickness does.
sST2 and Gal-3 not independently prognostic post-myectomy; leaves open mechanistic role in HCM progression.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common chromosomal abnormal heart disease. The pathophysiological mechanism of HCM is complex. Several studies have suggested that the level of Soluble ST2 (sST2) may be a biomarker of chronic systolic heart failure, however, the role of sST2 in HCM remains unclear. So we performed this study to analyze the role of Soluble ST2 (sST2), Galectin-3 (Gal-3) and its correlations with clinical prognosis of patients with hypertrophic cardiomyopathy (HCM) undergoing ventricular septal myectomy. METHODS: HCM patients who underwent modified Morrow surgery in our hospital during June 2016-June 2018 were included. We divided the patients into different groups stratified by sST2 and Gal-3 level. Besides, we included volunteers without heart disease for medical examination as normal controls. Biochemical analyses were conducted to identify the biomarkers difference. The predictive value of sST2 and Gal-3 on all-cause mortality was evaluated with Cox regression analysis. RESULTS: A total of 125 HCM patients were included in this present study. The sST2 and Gal-3 levels in HCM patients were significantly higher than that in control group (all P<0.001); there were significant differences in the incidence of all-cause mortality for HCM patients stratified by the sST2 and Gal-3 level; Cox univariate regression survival analysis showed that the hypertension (HR =1.19, 95% CI: 1.01-1.38), maximum wall thickness (HR =1.48, 95% CI: 1.04-1.98), Log sST2 (HR =1.02, 95% CI: 1.01-1.05), Log Gal-3 (HR =1.17, 95% CI: 1.09-1.32) were the predictors for all-cause mortality in patients with HCM, and Cox multivariate risk regression showed that maximum wall thickness was the independent predictors of all-cause mortality in patients with HCM (HR =1.63, 95% CI: 1.35-1.97). CONCLUSIONS: Even through sST2 and Gal-3 were not associated with clinical prognosis of patients with HCM undergoing ventricular septal myectomy, it may be involved in the progress of HCM, more studies are warranted to identify the potential mechanism and reverence value.
No takes yet. Share an insight, caveat, or question.
Song et al. (2020) conducted a cohort in Hypertrophic cardiomyopathy (HCM) undergoing ventricular septal myectomy (n=125). Soluble ST2 (sST2) and Galectin-3 (Gal-3) vs. Lower biomarker levels was evaluated on All-cause mortality (Log sST2 multivariate analysis) (HR 1.15, 95% CI 0.98-1.27, p=0.143). Elevated baseline levels of soluble ST2 and Galectin-3 were not independently associated with all-cause mortality in patients with hypertrophic cardiomyopathy undergoing ventricular septal myectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: